Structural heart innovation company Edwards Lifesciences (NYSE: EW) on Monday reported new two-year data from its TRISCEND II randomised trial demonstrating sustained clinical benefits for its EVOQUE transcatheter tricuspid valve replacement system, including reduced mortality when accounting for patient crossover. The findings were presented at the American College of Cardiology Annual Scientific Session (ACC.26).

These latest results confirm strong long-term performance of the EVOQUE system, including near elimination of tricuspid regurgitation, improved patient health status and quality of life, and no additional device-related safety risks. The study also showed significantly lower all-cause mortality when crossover patients were included in the analysis.

This update builds on 18-month TRISCEND II data presented at the European Society of Cardiology Congress in August 2025, which demonstrated clinical benefit in patients with severe tricuspid regurgitation and superior quality-of-life outcomes irrespective of baseline disease severity.

The EVOQUE system is approved in both the US and Europe, reinforcing Edwards Lifesciences' position in structural heart innovation and its focus on delivering clinically validated, patient-focused technologies.